03.05.19
Sartorius Stedim Biotech (SSB) and Novasep have entered into a collaboration agreement in the area of chromatography and single-use bioprocessing. Novasep provides various products and services to the life science industry based on specialized technologies, including the design, manufacture and control of resin-based batch and continuous chromatography systems.
Novasep’s BioSC platform and SSB’s single use technology will form the basis for the development of innovative chromatography systems. Systems currently on the market are designed for resins, but do not take full advantage of membrane chromatography capabilities. Optimally run membrane chromatography processes will provide an alternative to batch and continuous resin-based chromatography, with the goal of higher productivity, smaller scale operations and increased robustness.
“Membranes are the embodiment of process intensification. As the market leader in membrane chromatography, Sartorius Stedim Biotech aims to realize this potential and offer customers the full benefits of our Sartobind portfolio,” said Dr. Fritjof Linz, head of Separation at Sartorius Stedim Biotech. “We are happy to work with a highly competent partner like Novasep to introduce new membrane chromatography technology for flow through and capture applications.”
Nadège Laborde, president Process Solutions at Novasep, said, “This collaboration is a wonderful opportunity for Novasep and Sartorius Stedim Biotech, as it leverages the core capabilities of the two companies. The result of this venture will satisfy the latest market demands for continuous processing, process intensification, performance, and ease of use.”
Novasep’s BioSC platform and SSB’s single use technology will form the basis for the development of innovative chromatography systems. Systems currently on the market are designed for resins, but do not take full advantage of membrane chromatography capabilities. Optimally run membrane chromatography processes will provide an alternative to batch and continuous resin-based chromatography, with the goal of higher productivity, smaller scale operations and increased robustness.
“Membranes are the embodiment of process intensification. As the market leader in membrane chromatography, Sartorius Stedim Biotech aims to realize this potential and offer customers the full benefits of our Sartobind portfolio,” said Dr. Fritjof Linz, head of Separation at Sartorius Stedim Biotech. “We are happy to work with a highly competent partner like Novasep to introduce new membrane chromatography technology for flow through and capture applications.”
Nadège Laborde, president Process Solutions at Novasep, said, “This collaboration is a wonderful opportunity for Novasep and Sartorius Stedim Biotech, as it leverages the core capabilities of the two companies. The result of this venture will satisfy the latest market demands for continuous processing, process intensification, performance, and ease of use.”